Fact CheckerSign in

NCT06075433Recruiting

Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure

A Prospective, Multicenter, Observational Study to Evaluate the Efficacy and Safety of 1 Year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-Risk Procedure

Source: ClinicalTrials.gov · Last updated 21 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The objective of study is to evaluate the efficacy and safety of 1 year duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease according to the complex higher-risk (and indicated) procedure.

Status (registry)
Recruiting
Study type
Observational
Enrollment
1000 (estimated)
First submitted
4 Oct 2023
Start date
13 May 2022
Primary completion date
31 Dec 2027
Lead sponsor
Genoss Co., Ltd.
NCT number
NCT06075433

What you commit to

  • Study type: Observational
  • Planned participants: 1000
  • From 13 May 2022 to the primary completion date, 31 Dec 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients who have already received treatment with another DES (Drug Eluting Stent) or BMS (Bare Metal Stent) at the time of registration (However, other stent insertions are allowed due to failure of GENOSS DES insertion)

Other

  • Patients with cardiogenic shock at the time of hospitalization
  • Patients who are pregnant or planning to become pregnant
  • Patients with a life expectancy of less than 1 year
  • Patients participating in randomized controlled trials using other medical devices

Who the study is looking for

  • Patients of 19 and over
  • Patients with coronary artery disease treated with GENOSS SES
  • Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants

Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Wonju Severance Christian Hospital
Coordinator of this site? Confirm its status
WŏnjuSouth KoreaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.